The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

ABPA-related Bronchiectasis

Central bronchiectasis as sequela of allergic bronchopulmonary aspergillosis (ABPA) in asthmatic and cystic fibrosis patients, requiring fungal hypersensitivity control with corticosteroids and antifungals.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is ABPA-related Bronchiectasis?

ABPA pathogenesis: A. fumigatus colonization in viscous airway mucus → release of allergens (Asp f1-22) → IgE and IgG antibody responses, Th2 inflammation with eosinophilia, mast cell activation → bronchospasm, mucus plugging, airway wall destruction → central bronchiectasis (proximal larger airways, segmental and subsegmental, varicose pattern).

Stages (Patterson): Stage 1 (acute), Stage 2 (remission), Stage 3 (recurrent exacerbations), Stage 4 (corticosteroid-dependent asthma), Stage 5 (end-stage fibrosis with type II respiratory failure). Bronchiectasis develops in late stages with chronic infection by A. fumigatus and other organisms.

ABPA-related bronchiectasis is distinct: central (proximal) location with sparing of distal airways, finger-in-glove appearance from mucoid impaction, high-attenuation mucus on CT (calcium and metal salts in mucus, pathognomonic), preferential upper-lobe involvement.

Symptoms

Severe asthma exacerbations (steroid-dependent)
Productive cough with brown/black mucus plugs (expectoration of fungal balls)
Hemoptysis (sometimes from bronchiectasis or aspergilloma)
Wheezing, dyspnea
Recurrent pneumonia or atelectasis
Symptoms of cystic fibrosis (in CF-ABPA)
Constitutional symptoms during exacerbations (low-grade fever, malaise)

Risk Factors

Severe persistent asthma (1-2% develop ABPA)
Cystic fibrosis (7-15% develop ABPA)
Atopy (allergic rhinitis, eczema)
Chronic granulomatous disease (different mechanism, invasive disease)
Mannose-binding lectin deficiency
HLA-DR2/HLA-DR5 genotypes
CFTR mutations in non-CF asthma patients (some studies)
Environmental Aspergillus exposure (compost, decaying organic matter)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Difficult-to-control asthma with elevated total IgE
  • Recurrent pulmonary infiltrates in asthma patient
  • Cystic fibrosis patient with deteriorating lung function
  • Productive cough with brown/black mucus plugs
  • CT showing central bronchiectasis with mucoid impaction
  • Pulmonology and allergy referral for ABPA evaluation

Treatment Methods

01
Diagnostic workup (modified ISHAM 2013 criteria): predisposing condition (asthma or CF), required mandatory criteria (IgE total >1000 IU/mL, Aspergillus-specific IgE elevated), and ≥2 of (Aspergillus-specific IgG/precipitins, eosinophilia >500, characteristic chest imaging — central bronchiectasis or fleeting infiltrates)
02
CT chest features: central varicose bronchiectasis, mucoid impaction (finger-in-glove sign), high-attenuation mucus (specific), tree-in-bud nodules (smaller airway involvement), upper-lobe predominance
03
Systemic corticosteroids: prednisolone 0.5-0.75 mg/kg/day for 2 weeks, then tapered over 3-6 months; treat exacerbations with similar courses; aim for clinical and biochemical remission (IgE drop ≥35-50%)
04
Antifungal therapy: itraconazole 200 mg BID for 16 weeks (steroid-sparing, reduces exacerbations) — first-line; voriconazole or posaconazole if itraconazole ineffective or intolerance; therapeutic drug monitoring for itraconazole/voriconazole
05
Itraconazole considerations: drug interactions (CYP3A4 substrates), QT prolongation, hepatotoxicity monitoring, absorption variability
06
Omalizumab (anti-IgE) — emerging steroid-sparing agent: useful in steroid-dependent ABPA with persistent asthma; reduces exacerbations and IgE; consider with comorbid severe asthma
07
Mepolizumab and benralizumab (anti-IL-5/IL-5R): emerging evidence for steroid-sparing in eosinophilic ABPA-asthma
08
Bronchiectasis management: airway clearance (postural drainage, oscillatory PEP devices, hypertonic saline), inhaled bronchodilators, prevent secondary bacterial infection (annual influenza vaccine, pneumococcal vaccine, prompt antibiotics for exacerbations)
09
Mucus plug management: bronchoscopic removal for atelectasis or significant plugging; nebulized hypertonic saline (3-7%) for mucus thinning; inhaled DNase in CF
10
Cystic fibrosis-specific: CFTR modulators if eligible (elexacaftor-tezacaftor-ivacaftor), aggressive ABPA treatment due to additive lung damage, multidisciplinary CF center
11
Hemoptysis management: bronchial artery embolization for significant hemoptysis; consider aspergilloma in cavity, surgical resection in selected cases
12
Lung transplantation: end-stage disease (rare); ABPA recurrence in transplanted lung described
13
Long-term monitoring: serial total IgE (decrease confirms remission, increase predicts exacerbation), Aspergillus-specific IgE, eosinophil count, PFTs every 3-6 months, CT chest annually
14
Patient education: chronic disease, avoidance of high Aspergillus environments (compost, demolition sites), importance of vaccination and routine medical follow-up

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.